Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Effect & Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged 20 to 80 years~* men and women with coronary artery disease who had been treated with drug-eluting stent placement before \> 12 months~* patients who had remained in a stable condition with a single antiplatelet agent, aspirin~* patients who did not show any sign or symptom of the worsening of their angina within the last six months that required a coronary artery intervention, a coronary artery bypass, or coronary angiography~Exclusion Criteria:~* Patients who were taking another antiplatelet or anticoagulant drug such as clopidogrel, warfarin, or cilostazol in addition to aspirin, unless they could withdraw from such other drug/s, in which case they could be enrolled in the study after a two-week wash-out period~* Patients who were suffering from drug abuse or alcohol addiction~* hypersensitivity to clopidogrel or aspirin~* severe liver disease (ALT or AST ≥ 10 times the upper normal limit)~* active hemorrhage such as gastro-intestinal ulcer or intracranial hemorrhage~* a high risk of bleeding (blood coagulation disorder, uncontrolled severe hypertension, active bleeding, or history of severe bleeding)~* pregnant or lactating women~* women with childbearing potential who were not using an appropriate contraception method~* had medical or mental contra-indications to the study treatment

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Clopidogrel napadisilate (Type: EXPERIMENTAL): aspirin 100mg
- clopidogrel bisulfate (Type: ACTIVE_COMPARATOR): aspirin 100mg

Based on this trial design, predict the completion outcome and termination type (if applicable).